TVGN
Tevogen Bio Holdings Inc.
Biotechnology
Market Cap$1.48B
5Y Perf.-98.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TVGN vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$280M
5Y Perf.-94.1%
TVGN vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TVGN | FATE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.48B | $280M |
| Revenue (TTM) | $0.00 | $7M |
| Net Income (TTM) | $-31M | $-136M |
| Operating Margin | — | -22.2% |
| Total Debt | $3M | $78M |
| Cash & Equiv. | $1M | $47M |
TVGN vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TVGN
FATE
| Stock | Jan 22 | May 26 | Return |
|---|---|---|---|
| Tevogen Bio Holding… (TVGN) | 100 | 1.5 | -98.5% |
| Fate Therapeutics, … (FATE) | 100 | 5.9 | -94.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TVGN vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FATE leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Tevogen Bio Holdings Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TVGN
Tevogen Bio Holdings Inc.
The Income Pick
TVGN is the clearest fit if your priority is income & stability and growth exposure.
- beta 2.02
- EPS growth 47.6%
- Lower volatility, beta 2.02, current ratio 0.26x
Best for: income & stability and growth exposure
FATE
Fate Therapeutics, Inc.
The Long-Run Compounder
FATE carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 40.5% 10Y total return vs TVGN's -98.5%
- -51.2% revenue growth vs TVGN's -6.7%
- +143.0% vs TVGN's -85.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FATE | -51.2% revenue growth vs TVGN's -6.7% |
| Quality / Margins | TVGN | -5.3% margin vs FATE's -20.5% |
| Stability / Safety | TVGN | Beta 2.02 vs FATE's 2.17 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FATE | +143.0% vs TVGN's -85.6% |
| Efficiency (ROA) | FATE | -42.7% ROA vs TVGN's -6.9% |
TVGN vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
TVGN vs FATE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTVGNLAGGINGFATE
FATEFate Therapeutics, In…
2leads
TVGNTevogen Bio Holdings …
2leads
6 Total Categories
CATEGORYLEADERvs FATEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FATE1/1
Valuation MetricsMultiples, price ratios, and targets
TVGN1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TVGN3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
FATE6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FATE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FATE and TVGN operate at a comparable scale, with $7M and $0 in trailing revenue.
| Metric | TVGNTevogen Bio Holdi… | FATEFate Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $7M |
| EBITDAEarnings before interest/tax | -$30M | -$148M |
| Net IncomeAfter-tax profit | -$31M | -$136M |
| Free Cash FlowCash after capex | -$13M | -$88M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | -22.2% |
| Net MarginNet income ÷ Revenue | — | -20.5% |
| FCF MarginFCF ÷ Revenue | — | -13.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -26.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +13.5% | +38.6% |
FATE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
TVGN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | TVGNTevogen Bio Holdi… | FATEFate Therapeutics… |
|---|---|---|
| Market CapShares × price | $1.5B | $280M |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $312M |
| Trailing P/EPrice ÷ TTM EPS | -79.91x | -2.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 42.18x |
| Price / BookPrice ÷ Book value/share | — | 1.39x |
| Price / FCFMarket cap ÷ FCF | — | — |
TVGN leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
TVGN leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), TVGN scores 4/9 vs FATE's 2/9, reflecting mixed financial health.
| Metric | TVGNTevogen Bio Holdi… | FATEFate Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | — | -65.8% |
| ROA (TTM)Return on assets | -6.9% | -42.7% |
| ROICReturn on invested capital | — | -36.5% |
| ROCEReturn on capital employed | — | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 0.38x |
| Net DebtTotal debt minus cash | $2M | $31M |
| Cash & Equiv.Liquid assets | $1M | $47M |
| Total DebtShort + long-term debt | $3M | $78M |
| Interest CoverageEBIT ÷ Interest expense | -219.56x | — |
TVGN leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
FATE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FATE five years ago would be worth $318 today (with dividends reinvested), compared to $151 for TVGN. Over the past 12 months, FATE leads with a +143.0% total return vs TVGN's -85.6%. The 3-year compound annual growth rate (CAGR) favors FATE at -23.6% vs TVGN's -76.0% — a key indicator of consistent wealth creation.
| Metric | TVGNTevogen Bio Holdi… | FATEFate Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | -58.9% | +145.5% |
| 1-Year ReturnPast 12 months | -85.6% | +143.0% |
| 3-Year ReturnCumulative with dividends | -98.6% | -55.4% |
| 5-Year ReturnCumulative with dividends | -98.5% | -96.8% |
| 10-Year ReturnCumulative with dividends | -98.5% | +40.5% |
| CAGR (3Y)Annualised 3-year return | -76.0% | -23.6% |
FATE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TVGN and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
TVGN is the less volatile stock with a 2.02 beta — it tends to amplify market swings less than FATE's 2.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 98.6% from its 52-week high vs TVGN's 9.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TVGNTevogen Bio Holdi… | FATEFate Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 2.17x |
| 52-Week HighHighest price in past year | $75.50 | $2.46 |
| 52-Week LowLowest price in past year | $0.35 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +9.9% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 53.8 | 81.0 |
| Avg Volume (50D)Average daily shares traded | 34K | 1.9M |
Evenly matched — TVGN and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TVGN as "Hold" and FATE as "Buy".
| Metric | TVGNTevogen Bio Holdi… | FATEFate Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | — | $39.50 |
| # AnalystsCovering analysts | 1 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FATE leads in 2 of 6 categories (Income & Cash Flow, Total Returns). TVGN leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallTevogen Bio Holdings Inc. (TVGN)Leads 2 of 6 categories
Loading custom metrics...
TVGN vs FATE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TVGN or FATE a better buy right now?
Analysts rate Fate Therapeutics, Inc.
(FATE) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TVGN or FATE?
Over the past 5 years, Fate Therapeutics, Inc.
(FATE) delivered a total return of -96. 8%, compared to -98. 5% for Tevogen Bio Holdings Inc. (TVGN). Over 10 years, the gap is even starker: FATE returned +40. 5% versus TVGN's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TVGN or FATE?
By beta (market sensitivity over 5 years), Tevogen Bio Holdings Inc.
(TVGN) is the lower-risk stock at 2. 02β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 8% more volatile than TVGN relative to the S&P 500.
04Which has better profit margins — TVGN or FATE?
Tevogen Bio Holdings Inc.
(TVGN) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TVGN leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — TVGN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TVGN or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TVGN or FATE better for a retirement portfolio?
For long-horizon retirement investors, Fate Therapeutics, Inc.
(FATE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tevogen Bio Holdings Inc. (TVGN) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FATE: +40. 5%, TVGN: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TVGN and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.